Hanne Nygaard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hanne Nygaard has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Charlotte Suetta
Department of Clinical Medicine, Faculty of Health, University of Copenhagen , Blegdamsvej 3b, 2200 Copenhagen
4 shared publications - Pernille Hansen
Geriatric Research Unit, Department of Medicine, Copenhagen University Hospital, Herlev and Gentofte, Gentofte, Denmark
4 shared publications - Jesper Ryg
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
3 shared publications - Finn Erland Nielsen
Department of Emergency Medicine, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark
2 shared publications - Flemming Dela
Department of Biomedical Sciences, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
2 shared publications - Martin Schultz
Afdeling for Ældresygdomme og Lindrende Behandling, Københavns Universitetshospital - Amager og Hvidovre Hospital
2 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Elsevier in The Journal of Emergency Medicine
- Vol. 89, 58-61
Ischemic Stroke Occurring After Supraventricular Dysrhythmia Conversion With Carotid Massage: A Case Report
- 19 August 2026
- Published by Elsevier in The Journal of Emergency Medicine
- Vol. 89, 58-61
Open AccessIschemic Stroke Occurring After Supraventricular Dysrhythmia Conversion With Carotid Massage: A Case Report
- Open Access
- 6 July 2026
- Published by Danish Medical Association in Ugeskrift for Læger
- p. 1-9
Frailty in the older adults
Frailty is a core geriatric condition reflecting reduced physiological reserve and increased vulnerability to stressors. Frailty is associated with functional decline, hospitalisation, and mortality across healthcare settings. This review frames the key concept, clinical relevance, and assessment tools, primarily focusing on the Clinical Frailty Scale. The review highlights how frailty assessments can support clinical decision-making and individualised treatment based on older patients’ needs.
- 6 July 2026
- Published by Danish Medical Association in Ugeskrift for Læger
- p. 1-9
Open AccessFrailty in the older adults
Frailty is a core geriatric condition reflecting reduced physiological reserve and increased vulnerability to stressors. Frailty is associated with functional decline, hospitalisation, and mortality across healthcare settings. This review frames the key concept, clinical relevance, and assessment tools, primarily focusing on the Clinical Frailty Scale. The review highlights how frailty assessments can support clinical decision-making and individualised treatment based on older patients’ needs.
- Open Access
- 25 November 2025
- Published by Springer Nature in GeroScience
- Vol. 48 (2) , 1955-1966
GDF-15 plasma levels are elevated in mobility-limited older adults with frailty and sarcopenia—results from the BIOFRAIL study
Growth differentiation factor 15 (GDF-15) has been proposed as a potential biomarker for the geriatric syndromes of frailty and sarcopenia. This study investigated plasma GDF-15 as a biomarker associated with sarcopenia and frailty in a cohort of mobility-limited older adults. Patients (≥ 65 years) were recruited from a geriatric outpatient clinic for fall assessment. Frailty was identified using the Clinical Frailty Scale with a cut-off ≥ 5. Sarcopenia was defined according to the European Working Group on Sarcopenia in Older People 2. Plasma GDF-15 was analyzed using electrochemiluminescence assays (Meso Scale Discovery, Rockville, MD, USA). Receiver operating characteristic (ROC) analysis was performed to assess the diagnostic accuracy of GDF-15 for identifying frailty and sarcopenia. The optimum GDF-15 cut-off for frailty was determined using Youden’s Index. A total of 429 patients (age 79.6 ± 6.2 years, 64% female) were included. Of these, 16% had sarcopenia and 25% had frailty. Median GDF-15 levels in patients with/without sarcopenia and with/without frailty were 1916 pg/mL vs. 1569 pg/mL (p = 0.035), and 2252 pg/mL vs. 1438 pg/mL (p < 0.001), respectively. The area under the curve (AUC) for frailty was 0.681 (95% CI: 0.623–0.739) with an optimal cut-off of 2047 pg/mL. For sarcopenia, AUC was 0.577 (95% CI: 0.501–0.653). GDF-15 plasma levels appear to be elevated in mobility-limited older adults with frailty and sarcopenia. The diagnostic accuracy of GDF-15 for frailty appears of moderate magnitude, suggesting a potential clinical role of this biomarker in identifying frailty in mobility-limited older adults. In contrast, the diagnostic accuracy of GDF-15 for sarcopenia was poor. ClinicalTrials.gov Identifier: NCT05795556.
- 25 November 2025
- Published by Springer Nature in GeroScience
- Vol. 48 (2) , 1955-1966
Open AccessGDF-15 plasma levels are elevated in mobility-limited older adults with frailty and sarcopenia—results from the BIOFRAIL study
Growth differentiation factor 15 (GDF-15) has been proposed as a potential biomarker for the geriatric syndromes of frailty and sarcopenia. This study investigated plasma GDF-15 as a biomarker associated with sarcopenia and frailty in a cohort of mobility-limited older adults. Patients (≥ 65 years) were recruited from a geriatric outpatient clinic for fall assessment. Frailty was identified using the Clinical Frailty Scale with a cut-off ≥ 5. Sarcopenia was defined according to the European Working Group on Sarcopenia in Older People 2. Plasma GDF-15 was analyzed using electrochemiluminescence assays (Meso Scale Discovery, Rockville, MD, USA). Receiver operating characteristic (ROC) analysis was performed to assess the diagnostic accuracy of GDF-15 for identifying frailty and sarcopenia. The optimum GDF-15 cut-off for frailty was determined using Youden’s Index. A total of 429 patients (age 79.6 ± 6.2 years, 64% female) were included. Of these, 16% had sarcopenia and 25% had frailty. Median GDF-15 levels in patients with/without sarcopenia and with/without frailty were 1916 pg/mL vs. 1569 pg/mL (p = 0.035), and 2252 pg/mL vs. 1438 pg/mL (p < 0.001), respectively. The area under the curve (AUC) for frailty was 0.681 (95% CI: 0.623–0.739) with an optimal cut-off of 2047 pg/mL. For sarcopenia, AUC was 0.577 (95% CI: 0.501–0.653). GDF-15 plasma levels appear to be elevated in mobility-limited older adults with frailty and sarcopenia. The diagnostic accuracy of GDF-15 for frailty appears of moderate magnitude, suggesting a potential clinical role of this biomarker in identifying frailty in mobility-limited older adults. In contrast, the diagnostic accuracy of GDF-15 for sarcopenia was poor. ClinicalTrials.gov Identifier: NCT05795556.
- Open Access
- 27 May 2025
- Published by Springer Nature in European Geriatric Medicine
- Vol. 16 (4) , 1283-1293
Frailty is associated with a history of falls among mobility-limited older adults—cross-sectional multivariate analysis from the BIOFRAIL study
Key summary points: Aim: To identify differences in characteristics between mobility-limited older adults with a history of falls and those at risk of falling but who have not yet fallen. Findings: Frailty and muscle strength were characteristics distinguishing between older adults with a history of falls and those absent of falls despite an increased risk of falling. Message: Frailty should be incorporated alongside handgrip strength (HGS) and sit-to-stand (STS) tests into routine evaluations of mobility-limited older adults referred for fall assessment. Purpose: We aimed to identify differences in characteristics between mobility-limited older adults with a history of falls and those at risk of falling, and to identify the parameter with the strongest predictive value on the risk of falling. Methods: Data included anthropometry, HGS, 30-s and 5-reps STS tests, maximal isometric knee extensor strength, gait speed (6 m), postural balance (tandem test), and muscle mass (BIA). Frailty was assessed using the Clinical Frailty Scale (CFS) and sarcopenia was evaluated according to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) guidelines. Outcomes of falls (past year), and depression (Geriatric Depression Scale 15) were self-reported. Results: Totally, 505 mobility-limited older adults (mean age 79.7 ± 6.3 years, 64.8% females) were included. Of these, 400 (79.2%) had experienced one or more falls within the past year (fallers), while 105 (20.8%) had not experienced a fall (at risk). Patients with experienced falls were more likely to feel depressed, had reduced handgrip strength, and reduced performance in both STS tests compared to those who had not fallen. Frailty was the strongest individual parameter associated with a history of prior falls, even after adjusting for covariates such as depression and 30-s STS (aOR 3.80; 95% CI 1.70–8.50). Conclusions: Present study identified frailty as a key factor independently associated with a history of falls in this population. Additionally, handgrip strength and STS performance were key characteristics distinguishing between older adults with a history of falls within the past 12 months and those at risk of falling. Trial registration: NCT05795556
- 27 May 2025
- Published by Springer Nature in European Geriatric Medicine
- Vol. 16 (4) , 1283-1293
Open AccessFrailty is associated with a history of falls among mobility-limited older adults—cross-sectional multivariate analysis from the BIOFRAIL study
Key summary points: Aim: To identify differences in characteristics between mobility-limited older adults with a history of falls and those at risk of falling but who have not yet fallen. Findings: Frailty and muscle strength were characteristics distinguishing between older adults with a history of falls and those absent of falls despite an increased risk of falling. Message: Frailty should be incorporated alongside handgrip strength (HGS) and sit-to-stand (STS) tests into routine evaluations of mobility-limited older adults referred for fall assessment. Purpose: We aimed to identify differences in characteristics between mobility-limited older adults with a history of falls and those at risk of falling, and to identify the parameter with the strongest predictive value on the risk of falling. Methods: Data included anthropometry, HGS, 30-s and 5-reps STS tests, maximal isometric knee extensor strength, gait speed (6 m), postural balance (tandem test), and muscle mass (BIA). Frailty was assessed using the Clinical Frailty Scale (CFS) and sarcopenia was evaluated according to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) guidelines. Outcomes of falls (past year), and depression (Geriatric Depression Scale 15) were self-reported. Results: Totally, 505 mobility-limited older adults (mean age 79.7 ± 6.3 years, 64.8% females) were included. Of these, 400 (79.2%) had experienced one or more falls within the past year (fallers), while 105 (20.8%) had not experienced a fall (at risk). Patients with experienced falls were more likely to feel depressed, had reduced handgrip strength, and reduced performance in both STS tests compared to those who had not fallen. Frailty was the strongest individual parameter associated with a history of prior falls, even after adjusting for covariates such as depression and 30-s STS (aOR 3.80; 95% CI 1.70–8.50). Conclusions: Present study identified frailty as a key factor independently associated with a history of falls in this population. Additionally, handgrip strength and STS performance were key characteristics distinguishing between older adults with a history of falls within the past 12 months and those at risk of falling. Trial registration: NCT05795556
- Open Access
- 7 December 2024
- Published by Springer Nature in European Geriatric Medicine
- Vol. 16 (2) , 703-707
Applying both the 30-s and the 5-repetition sit-to-stand tests captures dissimilar groups and a broader spectrum of physical abilities in mobility-limited older individuals: results from the BIOFRAIL study
Purpose: We aimed to assess differences among older patients demonstrating low STS performance in the 30 s-STS and/or the 5r-STS. Methods: 30 s-STS and 5r-STS were used to assess lower limb muscle strength and function in older adults. Analysis involved 376 patients (≥ 65 years) from a geriatric outpatient clinic for fall assessment. Results: The mean age of patients was 79.8 (± 6.1) years (67% female). In total, 40.6% had low STS performance with 9.3% presenting only low 30 s-STS, 9.8% only low 5r-STS, and 21.5% low STS performance in both tests. Patients with low STS performance in both tests had lower gait speed, were more often frail, and had more prior falls compared to patients with low STS performance in one test only. Conclusion: The two STS tests are not interchangeable, and the use of both STS tests capture a wider range of physical abilities in mobility-limited older adults. Clinical trial registration: NCT05795556.
- 7 December 2024
- Published by Springer Nature in European Geriatric Medicine
- Vol. 16 (2) , 703-707
Open AccessApplying both the 30-s and the 5-repetition sit-to-stand tests captures dissimilar groups and a broader spectrum of physical abilities in mobility-limited older individuals: results from the BIOFRAIL study
Purpose: We aimed to assess differences among older patients demonstrating low STS performance in the 30 s-STS and/or the 5r-STS. Methods: 30 s-STS and 5r-STS were used to assess lower limb muscle strength and function in older adults. Analysis involved 376 patients (≥ 65 years) from a geriatric outpatient clinic for fall assessment. Results: The mean age of patients was 79.8 (± 6.1) years (67% female). In total, 40.6% had low STS performance with 9.3% presenting only low 30 s-STS, 9.8% only low 5r-STS, and 21.5% low STS performance in both tests. Patients with low STS performance in both tests had lower gait speed, were more often frail, and had more prior falls compared to patients with low STS performance in one test only. Conclusion: The two STS tests are not interchangeable, and the use of both STS tests capture a wider range of physical abilities in mobility-limited older adults. Clinical trial registration: NCT05795556.
- Open Access
- 28 September 2024
- Published by Springer Nature in European Geriatric Medicine
- Vol. 15 (6) , 1899-1908
The hazard of mortality across different levels of frailty are increased among patients with high Braden scores
Purpose: To examine the prognostic accuracy of the Clinical Frailty Scale (CFS) and Braden Scale (BS) separately and combined for 90-day mortality. Furthermore, to examine the effect of frailty on mortality depending on different levels of the Braden score. Methods: The study included acutely admitted medical patients ≥ 65 years. We used an optimum cutoff for CSF and BS at ≥ 4 and ≤ 19, respectively. CFS categorized frailty as Non-frail (< 4), Frail (4–5), and Severely frail (> 5). Prognostic accuracy was estimated by the area under the receiver operating characteristic curves (AUROC) with 95% confidence intervals (CI). Cox regression analysis was used to compute the adjusted hazard ratio (aHR) for mortality. Results: The mean age among 901 patients (54% female) was 79 years. The AUROC for CFS and BS was 0.65 (CI95% 0.60–0.71) and 0.71 (CI95% 0.66–0.76), respectively. aHR for mortality of CFS ≥ 4, BS ≤ 19, and combined were 2.3 (CI95% 1.2–4.2), 1.9 (CI95% 1.3–2.9), and 1.9 (CI95% 1.3–2.8), respectively. For BS > 19, the aHR for mortality was 2.2 (CI95% 1.0–4.8) and 3.5 (CI95% 1.4–8.6) for ‘frail’ and ‘severely frail’, respectively. aHR for BS ≤ 19 was 1.1 (CI95% 0.4–3.2) and 1.3 (CI95% 0.5–3.7) for ‘frail’ and ‘severely frail’, respectively. Conclusion: Although CFS and BS were associated with 90-day mortality among older acutely admitted medical patients, the prognostic accuracy was poor-to-moderate, and the combination of CFS and BS did not improve the prognostic accuracy. However, the hazard of mortality across different levels of frailty groups were particularly increased among patients with high BS scores. Graphical
- 28 September 2024
- Published by Springer Nature in European Geriatric Medicine
- Vol. 15 (6) , 1899-1908
Open AccessThe hazard of mortality across different levels of frailty are increased among patients with high Braden scores
Purpose: To examine the prognostic accuracy of the Clinical Frailty Scale (CFS) and Braden Scale (BS) separately and combined for 90-day mortality. Furthermore, to examine the effect of frailty on mortality depending on different levels of the Braden score. Methods: The study included acutely admitted medical patients ≥ 65 years. We used an optimum cutoff for CSF and BS at ≥ 4 and ≤ 19, respectively. CFS categorized frailty as Non-frail (< 4), Frail (4–5), and Severely frail (> 5). Prognostic accuracy was estimated by the area under the receiver operating characteristic curves (AUROC) with 95% confidence intervals (CI). Cox regression analysis was used to compute the adjusted hazard ratio (aHR) for mortality. Results: The mean age among 901 patients (54% female) was 79 years. The AUROC for CFS and BS was 0.65 (CI95% 0.60–0.71) and 0.71 (CI95% 0.66–0.76), respectively. aHR for mortality of CFS ≥ 4, BS ≤ 19, and combined were 2.3 (CI95% 1.2–4.2), 1.9 (CI95% 1.3–2.9), and 1.9 (CI95% 1.3–2.8), respectively. For BS > 19, the aHR for mortality was 2.2 (CI95% 1.0–4.8) and 3.5 (CI95% 1.4–8.6) for ‘frail’ and ‘severely frail’, respectively. aHR for BS ≤ 19 was 1.1 (CI95% 0.4–3.2) and 1.3 (CI95% 0.5–3.7) for ‘frail’ and ‘severely frail’, respectively. Conclusion: Although CFS and BS were associated with 90-day mortality among older acutely admitted medical patients, the prognostic accuracy was poor-to-moderate, and the combination of CFS and BS did not improve the prognostic accuracy. However, the hazard of mortality across different levels of frailty groups were particularly increased among patients with high BS scores. Graphical
- Open Access
- 7 March 2024
- Published by Elsevier in The Journal of Frailty & Aging
- Vol. 13 (2) , 91-97
Co-Occurrence of Sarcopenia and Frailty in Acutely Admitted Older Medical Patients: Results from the Copenhagen PROTECT Study
Sarcopenia and frailty are often used interchangeably in clinical practice yet represent two distinct conditions and require different therapeutic approaches. The literature regarding the co-occurrence of both conditions in older patients is scarce as most studies have investigated the prevalence of sarcopenia and frailty separately. We aim to evaluate the prevalence and co-occurrence of sarcopenia and frailty in a large sample of acutely admitted older medical patients. Secondary analyses using cross-sectional data from the Copenhagen PROTECT study. Patients were included from the acute medical ward at Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, between November 2019 and November 2021. Acutely admitted older medical patients (≥65 years). Handgrip strength (HGS) was investigated using a handheld dynamometer. Lean mass (SMI) was investigated using direct-segmental multifrequency bioelectrical impedance analyses (DSM-BIA). Low HGS, low SMI, and sarcopenia were defined according to the recent definitions from the European Working Group on Sarcopenia in Older People (EWGSOP2). The Clinical Frailty Scale (CFS) was used to evaluate frailty, with a value > 5 indicating the presence of frailty. Patients were enrolled and tested within 24 hours of admission. This study included 638 patients (mean age: 78.2±7.6, 55% female) with complete records of SMI, HGS, and the CFS. The prevalence of low HGS, low SMI, sarcopenia, and frailty were 39.0%, 33.1%, 19.7%, and 39.0%, respectively. Sarcopenia and frailty co-occurred in 12.1% of the patients. It is well-known that sarcopenia and frailty represent clinical manifestations of ageing and overlap in terms of the impairment in physical function observed in both conditions. Our results demonstrate that sarcopenia and frailty do not necessarily co-occur within the older acutely admitted patient, highlighting the need for separate assessments of frailty and sarcopenia to ensure the accurate characterization of the health status of older patients.
- 7 March 2024
- Published by Elsevier in The Journal of Frailty & Aging
- Vol. 13 (2) , 91-97
Open AccessCo-Occurrence of Sarcopenia and Frailty in Acutely Admitted Older Medical Patients: Results from the Copenhagen PROTECT Study
Sarcopenia and frailty are often used interchangeably in clinical practice yet represent two distinct conditions and require different therapeutic approaches. The literature regarding the co-occurrence of both conditions in older patients is scarce as most studies have investigated the prevalence of sarcopenia and frailty separately. We aim to evaluate the prevalence and co-occurrence of sarcopenia and frailty in a large sample of acutely admitted older medical patients. Secondary analyses using cross-sectional data from the Copenhagen PROTECT study. Patients were included from the acute medical ward at Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, between November 2019 and November 2021. Acutely admitted older medical patients (≥65 years). Handgrip strength (HGS) was investigated using a handheld dynamometer. Lean mass (SMI) was investigated using direct-segmental multifrequency bioelectrical impedance analyses (DSM-BIA). Low HGS, low SMI, and sarcopenia were defined according to the recent definitions from the European Working Group on Sarcopenia in Older People (EWGSOP2). The Clinical Frailty Scale (CFS) was used to evaluate frailty, with a value > 5 indicating the presence of frailty. Patients were enrolled and tested within 24 hours of admission. This study included 638 patients (mean age: 78.2±7.6, 55% female) with complete records of SMI, HGS, and the CFS. The prevalence of low HGS, low SMI, sarcopenia, and frailty were 39.0%, 33.1%, 19.7%, and 39.0%, respectively. Sarcopenia and frailty co-occurred in 12.1% of the patients. It is well-known that sarcopenia and frailty represent clinical manifestations of ageing and overlap in terms of the impairment in physical function observed in both conditions. Our results demonstrate that sarcopenia and frailty do not necessarily co-occur within the older acutely admitted patient, highlighting the need for separate assessments of frailty and sarcopenia to ensure the accurate characterization of the health status of older patients.
- Open Access
- 30 December 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (1) , 201
Triage Strategies Based on C-Reactive Protein Levels and SARS-CoV-2 Tests among Individuals Referred with Suspected COVID-19: A Prospective Cohort Study
C-reactive protein (CRP) has prognostic value in hospitalized patients with COVID-19; the importance of CRP in pre-hospitalized patients remains to be tested. Methods: Individuals with symptoms of COVID-19 had a SARS-CoV-2 PCR oropharyngeal swab test, and a measurement of CRP was performed at baseline, with an upper reference range of 10 mg/L. After 28 days, information about possible admissions, oxygen treatments, transfers to the ICU, or deaths was obtained from the patient files. Using logistic regression, the prognostic value of the CRP and SARS-CoV-2 test results was evaluated. Results: Among the 1006 patients included, the SARS-CoV-2 PCR test was positive in 59, and the CRP level was elevated (>10 mg/L) in 131. In total, 59 patients were hospitalized, only 3 of whom were SARS-CoV-2 positive, with elevated CRP (n = 2) and normal CRP (n = 1). The probability of being hospitalized with elevated CRP was 4.21 (95%CI 2.38–7.43, p < 0.0001), while the probability of being hospitalized with SARS-CoV-2 positivity alone was 0.85 (95%CI 0.26–2.81, p = 0.79). Conclusions: CRP is not a reliable predictor for the course of SARS-CoV-2 infection in pre-hospitalized patients. CRP, while not a SARS-CoV-2 positive test, had prognostic value in the total population of patients presenting with COVID-19-related symptoms.
- 30 December 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (1) , 201
Open AccessTriage Strategies Based on C-Reactive Protein Levels and SARS-CoV-2 Tests among Individuals Referred with Suspected COVID-19: A Prospective Cohort Study
C-reactive protein (CRP) has prognostic value in hospitalized patients with COVID-19; the importance of CRP in pre-hospitalized patients remains to be tested. Methods: Individuals with symptoms of COVID-19 had a SARS-CoV-2 PCR oropharyngeal swab test, and a measurement of CRP was performed at baseline, with an upper reference range of 10 mg/L. After 28 days, information about possible admissions, oxygen treatments, transfers to the ICU, or deaths was obtained from the patient files. Using logistic regression, the prognostic value of the CRP and SARS-CoV-2 test results was evaluated. Results: Among the 1006 patients included, the SARS-CoV-2 PCR test was positive in 59, and the CRP level was elevated (>10 mg/L) in 131. In total, 59 patients were hospitalized, only 3 of whom were SARS-CoV-2 positive, with elevated CRP (n = 2) and normal CRP (n = 1). The probability of being hospitalized with elevated CRP was 4.21 (95%CI 2.38–7.43, p < 0.0001), while the probability of being hospitalized with SARS-CoV-2 positivity alone was 0.85 (95%CI 0.26–2.81, p = 0.79). Conclusions: CRP is not a reliable predictor for the course of SARS-CoV-2 infection in pre-hospitalized patients. CRP, while not a SARS-CoV-2 positive test, had prognostic value in the total population of patients presenting with COVID-19-related symptoms.
- 1 November 2020
- Vol. 67 (11)
Comparison between temporal and rectal temperature measurement
Introduction: Various digital thermometers for non-invasive use have been used increasingly in Danish hospitals, including the temporal artery thermometer (TAT). However, previous studies have concluded that the accuracy of the TAT is unsatisfying for paediatric, surgical, cancer and intensive care patients. The purpose of this study was to compare the accuracy of the TAT with that of a conventional rectal thermometer (REC) within acutely admitted medical patients at an emergency department. Methods: This was a prospective, comparative study. For two months, 381 patients were included. At a maximum interval of seven minutes, the temperature was measured first with a temporal artery thermometer and then with an REC. The measurements were analysed in a Bland-Altman plot, and the sensitivity and specificity of the TAT were calculated. Results: The differences between the TAT and the REC ranged from -1.7 degrees C to 1.7 degrees C. The mean of the difference was drawn in the Bland-Altman plot through 0.17 with a standard deviation of 0.47. The sensitivity and specificity were calculated to 67% and 96%, respectively. Conclusions: Based on this study, we do not recommend the use of the TAT as an alternative to an REC for non-invasive measuring of the body temperature in acutely admitted medical patients.
- 1 November 2020
- Vol. 67 (11)
Comparison between temporal and rectal temperature measurement
Introduction: Various digital thermometers for non-invasive use have been used increasingly in Danish hospitals, including the temporal artery thermometer (TAT). However, previous studies have concluded that the accuracy of the TAT is unsatisfying for paediatric, surgical, cancer and intensive care patients. The purpose of this study was to compare the accuracy of the TAT with that of a conventional rectal thermometer (REC) within acutely admitted medical patients at an emergency department. Methods: This was a prospective, comparative study. For two months, 381 patients were included. At a maximum interval of seven minutes, the temperature was measured first with a temporal artery thermometer and then with an REC. The measurements were analysed in a Bland-Altman plot, and the sensitivity and specificity of the TAT were calculated. Results: The differences between the TAT and the REC ranged from -1.7 degrees C to 1.7 degrees C. The mean of the difference was drawn in the Bland-Altman plot through 0.17 with a standard deviation of 0.47. The sensitivity and specificity were calculated to 67% and 96%, respectively. Conclusions: Based on this study, we do not recommend the use of the TAT as an alternative to an REC for non-invasive measuring of the body temperature in acutely admitted medical patients.